



## **Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2007; Podcast to be Available Following Conference Call**

August 3, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 3, 2006--Alkermes, Inc. (Nasdaq: ALKS) will host a conference call at 4:30 p.m. EDT on Tuesday, August 8, 2006 to discuss the Company's financial results for its first quarter of fiscal 2007. Management will review the quarter and provide an update on the Company.

The conference call will be webcast on the investor relations section of Alkermes' website at [www.alkermes.com](http://www.alkermes.com) or may be accessed by dialing 1-866-818-1223 for domestic callers and 1-703-639-1376 for international callers. The conference call ID number is 943375.

A replay of the conference call will be available from 7:30 p.m. EDT on Tuesday, August 8, 2006 through 5:00 p.m. EDT on Sunday, August 13, 2006, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 943375. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Tuesday, August 15, 2006.

Alkermes, Inc. is a biotechnology company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company has two commercial products. RISPERSDAL(R) CONSTA(R) ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. VIVITROL(R) (naltrexone for extended-release injectable suspension) is the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and is marketed in the United States primarily by Cephalon, Inc. The Company has a pipeline of extended-release injectable products and pulmonary products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies; and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

VIVITROL(R) is a trademark of Cephalon, Inc. and RISPERSDAL(R) CONSTA(R) is a registered trademark of Johnson & Johnson Corporation.

CONTACT: Alkermes, Inc. Debra Koufos, 617-583-6220 Associate, Corporate Communications SOURCE: Alkermes, Inc.